Credit Suisse Ag Kala Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.3 - $1.31 $7 - $34	26 New	26 $0
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.74 $21,406 - $50,563	-18,454 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$2.62 - $5.43 $1,642 - $3,404	-627 Reduced 3.29%	18,454 $49,000
Q2 2021 Aug 16, 2021	BUY	$5.06 - $8.15 $991 - $1,597	196 Added 1.04%	19,081 $100,000
Q1 2021 May 14, 2021	SELL	$6.24 - $9.58 $128,057 - $196,600	-20,522 Reduced 52.08%	18,885 $127,000

Q4 2020 Feb 12, 2021	BUY	$6.28 - $8.79 $94,187 - $131,832	14,998 Added 61.44%	39,407 $267,000
Q3 2020 Nov 13, 2020	BUY	$7.5 - $11.11 $27,390 - $40,573	3,652 Added 17.59%	24,409 $183,000
Q2 2020 Aug 12, 2020	BUY	$8.33 - $13.79 $172,905 - $286,239	20,757 New	20,757 $218,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $10.4M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.